ID   KEN-3
AC   CVCL_W124
SY   KEN3; Ken3
DR   Wikidata; Q54899804
RX   PubMed=1351514;
RX   PubMed=8718548;
RX   PubMed=15677628;
CC   Population: Japanese.
CC   Doubling time: 76.9 hours (PubMed=1351514).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C5233; Ovarian fibrosarcoma
DI   ORDO; Orphanet_2030; Fibrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   17Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 29-06-23; Version: 8
//
RX   PubMed=1351514;
RA   Kiyozuka Y., Nishimura H., Iwanaga S., Yakushiji M., Ito K.,
RA   Nakano S., Tamori N., Adachi S., Noda T., Imai S.;
RT   "Establishment and characterization of human ovarian fibrosarcoma cell
RT   line and its sensitivity to anticancer agents.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 44:461-468(1992).
//
RX   PubMed=8718548;
RA   Murakami F.;
RT   "Cytotoxic action of monoclonal antibodies OC125 and SH-9 on ovarian
RT   cancer cell lines.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 48:125-132(1996).
//
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
//